<DOC>
	<DOCNO>NCT02193971</DOCNO>
	<brief_summary>- Study objectives 1 . To compare safety long-term efficacy coronary stenting biostable polymer everolimus-eluting coronary stent system ( Promus PremierTM ) biodegradable polymer biolimus-eluting coronary stent system ( Biomatrix® , Biomatrix Flex® Nobori® ) patient acute coronary syndrome 2 . To compare efficacy safety 5 mg prasugrel maintenance therapy compare 10 mg prasugrel maintenance therapy patient acute coronary syndrome undergo percutaneous coronary intervention - Study design : Prospective , open-label , 2-by-2 multifactorial , randomize , multicenter trial test follow CHD patient 1 . Non-inferiority biostable polymer everolimus-eluting stent ( Promus PremierTM ) compare biodegradable polymer biolimus-eluting coronary stent system ( Biomatrix® , Biomatrix Flex® Nobori® ) term patient-oriented composite outcome 2 . Non-inferiority 5 mg compare 10 mg dose prasugrel maintenance term major adverse cardiovascular event</brief_summary>
	<brief_title>Harmonizing Optimal Strategy Treatment Coronary Artery Diseases III Trial - Comparison REDUCTION PrasugrEl Dose &amp; POLYmer TECHnology ACS Patients ( HOST III Trial - REDUCE POLYTECH RCT )</brief_title>
	<detailed_description>About 3400 patient derive population Korean patient acute coronary syndrome receive percutaneous coronary intervention enrol present trial . All patient receive load dose aspirin ( 300 mg ) prasugrel ( 60 mg bolus ) administered.Following angiography , patient significant diameter stenosis &gt; 50 % coronary artery graft vessel visual estimation document myocardial ischemia symptom angina , lesion eligible coronary intervention without exclusion criterion , randomize 1:1 either receive either Promus Premier Biomatrix® Biomatrix Flex® Nobori® . At 1-month clinical follow-up , patient eligible antiplatelet comparison additionally randomize 1:1 either receive reduce dose prasugrel ( 5 mg daily ) conventional dose ( 10 mg daily ) . The exclusion criterion ( age ≥75 year , body weight &lt; 60 kg , history TIA stroke ) classify observational cohort . Post-PCI , dual antiplatelet therapy recommend least 1 year . Follow-up data collect 3-year index procedure .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Subject must ≥ 18 year Subject able verbally confirm understandings risk , benefit treatment alternative receive PCI he/she his/her legally authorize representative provide write informed consent prior study related procedure . Subject must culprit lesion native coronary artery significant stenosis ( &gt; 50 % visual estimate ) eligible stent implantation Subject must clinical diagnosis acute coronary syndrome Following patient enrolled stent comparison , exclude antiplatelet comparison . They classify observational cohort . Subjects ≥75 year Body weight &lt; 60 kg History TIA stroke The patient know hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Prasugrel , Ticagrelor , Biolimus , Everolimus , Contrast medium ( Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . ) Patients active pathologic bleed Gastrointestinal genitourinary bleeding within prior 3 month , major surgery within 2 month . Systemic ( intravenous ) Biolimus , everolimus use within 12 month . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . History bleed diathesis , know coagulopathy ( include heparininduced thrombocytopenia ) , refuse blood transfusion Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Prasugrel</keyword>
</DOC>